Sumati V. Gupta
( out of 121 reviews )

Sumati V. Gupta, MD

Languages spoken: English, Marathi, Hindi

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Urology
Salt Lake City
801-585-0250

Veterans Administration Medical Center

Salt Lake City

  • Sumati Gupta, MD, is a tenured Associate Professor in the Division of Oncology, Department of Medicine, at University of Utah‘s Huntsman Cancer Institute (HCI).

    Dr. Gupta specializes in the treatment of Genitourinary Cancers (bladder, kidney, prostate and testicular cancer) and the treatment of older adults with cancer (Geriatric Oncology).

    Dr. Gupta earned her medical degree from University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. Dr. Gupta completed fellowship in Medical Oncology at the University of Utah.

    Dr. Gupta serves as the medical director of the Geriatric Oncology clinic (GOAL clinic) and is co- Principal Investigator of the Total Cancer Care project at HCI. Dr. Gupta is a member of the Genitourinary Cancers program and Experimental Therapeutics at HCI and co-chairs the Genitourinary Cancers Research Interest Group in the ORIEN consortium. Dr. Gupta serves on the Data Safety and Monitoring Committee at HCI. As a clinical investigator and physician scientist, Dr. Gupta conducts clinical trials at Huntsman Cancer Institute and investigates mechanisms of treatment resistance to translate to more effective treatment of cancer.

    Dr. Gupta also practices at the Salt Lake City Veteran Administration hospital where she treats veterans, teaches residents and fellows, performs research in Genitourinary Cancers and chairs the VISN-19 Interdisciplinary Cancer Committee.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 121 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    February 16, 2025
    HUNTSMAN CANCER CENTER

    she is very nice

    February 11, 2025
    HUNTSMAN CANCER CENTER

    The Best.

    January 20, 2025
    HUNTSMAN CANCER CENTER

    dr. Gupta is a very good Dr. she tried me very well.

    January 19, 2025
    HUNTSMAN CANCER CENTER

    very thorough and genuine in her concern for me and ensuring i get the proper treatment. Setting me up with everything i need to be successful in response to the prescribed treatment.

    January 14, 2025
    HUNTSMAN CANCER CENTER

    Always positive and help me feel reassured.

    November 26, 2024
    HUNTSMAN CANCER CENTER

    Excellent about explaining my treatment

    November 23, 2024
    HUNTSMAN CANCER CENTER

    she is very nice and a good doctor. She knows what she is doing

    November 21, 2024
    HUNTSMAN CANCER CENTER

    Dr. Gupta's care brought me back from the brink.

    November 09, 2024
    HUNTSMAN CANCER CENTER

    I have complete confidence in doc and her staff

    See More Patient Comments

  • Sumati Gupta, MD, is a tenured Associate Professor in the Division of Oncology, Department of Medicine, at University of Utah‘s Huntsman Cancer Institute (HCI).

    Dr. Gupta specializes in the treatment of Genitourinary Cancers (bladder, kidney, prostate and testicular cancer) and the treatment of older adults with cancer (Geriatric Oncology).

    Dr. Gupta earned her medical degree from University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. Dr. Gupta completed fellowship in Medical Oncology at the University of Utah.

    Dr. Gupta serves as the medical director of the Geriatric Oncology clinic (GOAL clinic) and is co- Principal Investigator of the Total Cancer Care project at HCI. Dr. Gupta is a member of the Genitourinary Cancers program and Experimental Therapeutics at HCI and co-chairs the Genitourinary Cancers Research Interest Group in the ORIEN consortium. Dr. Gupta serves on the Data Safety and Monitoring Committee at HCI. As a clinical investigator and physician scientist, Dr. Gupta conducts clinical trials at Huntsman Cancer Institute and investigates mechanisms of treatment resistance to translate to more effective treatment of cancer.

    Dr. Gupta also practices at the Salt Lake City Veteran Administration hospital where she treats veterans, teaches residents and fellows, performs research in Genitourinary Cancers and chairs the VISN-19 Interdisciplinary Cancer Committee.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Medical Oncology - University of Utah, Huntsman Cancer Institute Fellow
    Fellowship Geriatric Medicine - Baylor College of Medicine Fellow
    Residency Internal Medicine - Nassau University Medical Center Resident
    Professional Medical Medical School - King Edward Memorial hospital and Seth G.S Medical College, Mumbai, India MD
    Undergraduate High School - Atomic Energy Junior College Higher Secondary Certificate

    Selected Publications

    Journal Article

    1. Swami U, Hong A, Diessner B, Young C, Bunner SH, Xie B, Ramaswamy K, Chastek B, Chaar NE, Gupta S (2024). Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future Oncol, 1-14. (Read full article)
    2. Tripathi N, Gebrael G, Chigarira B, Sahu KK, Balasubramanian I, Caparas C, Mathew Thomas V, Cohan JN, Pelletier K, Maughan BL, Agarwal N, Swami U, Gupta S (2024). Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis. Cancers (Basel), 16(11). (Read full article)
    3. Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta S (2024). Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO Precis Oncol, 8, e2300697. (Read full article)
    4. Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami U (2024). Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US. JAMA Netw Open, 7(5), e249417. (Read full article)
    5. Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC Cancer, 24(1), 493. (Read full article)
    6. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan BL (2024). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). Oncologist, 29(5), 450-e725. (Read full article)
    7. Necchi A, Pouessel D, Leibowitz R, Gupta S, Flchon A, Garca-Donas J, Bilen MA, Debruyne PR, Milowsky MI, Friedlander T, Maio M, Gilmartin A, Li X, Veronese ML, Loriot Y (2023). Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Ann Oncol, 35(2), 200-210. (Read full article)
    8. Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Flchon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot Y (2024). Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol, JCO2202835. (Read full article)
    9. Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Flchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthlmy P, Tagawa ST (2024). TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Ann Oncol. (Read full article)
    10. Li H, Sahu KK, Kumar SA, Tripathi N, Sayegh N, Nordblad B, Chigarira B, Gupta S, Maughan BL, Agarwal N, Swami U (2023). Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. Cancers (Basel), 15(21). (Read full article)
    11. Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, OKeeffe JA, Lewis N, Pavlakis GN, Thompson JA (2023). First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. J Immunother Cancer, 11(10). (Read full article)
    12. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL (2022). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. Oncologist, 28(8), 737-e693. (Read full article)
    13. Doroshow DB, ODonnell PH, Hoffman-Censits JH, Gupta SV, Vaishampayan U, Heath EI, Garcia P, Zhao Q, Yu M, Milowsky MI, Galsky MD (2023). Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO Precis Oncol, 7, e2300095. (Read full article)
    14. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC Res Notes, 16(1), 16. (Read full article)
    15. Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, ODay SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta S (2022). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. J Immunother Cancer, 11(1). (Read full article)
    16. Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri TK (2022). Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. Oncologist. (Read full article)
    17. Sahu KK, Johnson ED, Butler K, Li H, Boucher KM, Gupta S (2022). Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool. Geriatrics (Basel), 7(6). (Read full article)
    18. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol, 40(11), 493.e1-493.e7. (Read full article)
    19. Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583. (Read full article)
    20. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, MK-6482-004 Investigators (2021). Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med, 385(22), 2036-2046. (Read full article)
    21. Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP (2021). Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int, 128(5), 607-614. (Read full article)
    22. Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis GN (2021). Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. J Immunother Cancer, 9(11). (Read full article)
    23. Lyou Y, Rosenberg JE, Hoffman-Censits J, Quinn DI, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Xu C, Andresen C, Moran S, Daneshmand S, Bajorin D, Pal SK, Grivas P (2021). Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. (Read full article)
    24. Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, Gross C, Gupta S, Hollis G, Hubbard J, Jagsi R, Keating NL, Kessler E, Koll T, Korc-Grodzicki B, McKoy JM, Misra S, Moon D, OConnor T, Owusu C, Rosko A, Russell M, Sedrak M, Siddiqui F, Stella A, Stirewalt DL, Subbiah IM, Tew WP, Williams GR, Hollinger L, George GV, Sundar H (2021). NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw, 19(9), 1006-1019. (Read full article)
    25. Bleicher J, McGuire LE, Robbins RB, Johnson JE, Fischbuch S, Gupta S, Beck AC, Cohan JN (2021). Preoperative Advance Care Planning for Older Adults Undergoing Major Abdominal Surgery. Am J Hosp Palliat Care, 10499091211020276. (Read full article)
    26. Grivas P, Kiedrowski LA, Sonpavde GP, Gupta SV, Thomas RA, Gourdin TS, Hardin AI, Hamann KM, Faltas BM, Vogelzang NJ (2021). Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. Bladder Cancer, 7(2), 143-148. (Read full article)
    27. Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S (2021). Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer, 21(1), 593. (Read full article)
    28. Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Wang H, Reyes M, Moran S, Daneshmand S, Bajorin D, Pal SK (2020). Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol, 78(6), 916-924. (Read full article)
    29. Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer, 8(2). (Read full article)
    30. Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP (2019). Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. Eur Urol Oncol, 3(5), 695-699. (Read full article)
    31. Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, GS, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal SK (2020). Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol, 38(16), 1797-1806. (Read full article)
    32. Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg JE (2020). Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer, 126(11), 2597-2606. (Read full article)
    33. Neeraj Agarwal, Roberto Nussenzveig, Andrew W Hahn, John M Hoffman, Kathryn Morton, Sumati Gupta, Julia Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth Boucher, Benjamin Haaland, Benjamin L Maughan (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer PMID: 31937614  DOI:10.1158/1078-0402 CCR-19 -2591  . Clin Cancer Res, 26(9), 2104-2110.
    34. Russell W Madison, Sumati V Gupta, Yasir Y Elamin, Douglas I Lin, Sumanta K Pal, Andrea Necchi, Vincent A Miller, Jeffrey S Ross, Jon H Chung, Brian M Alexander, Alexa B Schrock, John V Heymach, Prasanth Reddy, Siraj Ali (2020 May). Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions PMID: 31985116  DOI: 10.1111/bju.15006. BJU Int, 125(5), 739-746.
    35. Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926. (Read full article)
    36. Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer BC (2019). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol, 38(1), 1.e1-1.e10. (Read full article)
    37. Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, ODonnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE (2018). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 125(4), 533-540. (Read full article)
    38. Gupta S, Albertson DJ, Parnell TJ, Butterfield A, Weston A, Pappas LM, Dalley B, OShea JM, Lowrance WT, Cairns BR, Schiffman JD, Sharma S (2019 Jan). Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma.Epub 2018 Oct 9PMID: 30301863 DOI: 10.1158/1535-7163.MCT-17-0957. Mol Cancer Ther, 18(1), 185-195.
    39. Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grnwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF (2018). Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov, 8(7), 812-821. (Read full article)
    40. Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P (2018). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 124(10), 2115-2124. (Read full article)
    41. Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533. (Read full article)
    42. Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ (2017). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer, 16(2), e373-e382. (Read full article)
    43. Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.LID - S1470-2045(18)30107-4 [pii]LID - 10.1016/S1470-2045(18)30107-4 [doi]. Lancet Oncol, 19, 451-460. (Read full article)
    44. Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma S (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924. (Read full article)
    45. Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Fam Cancer, 16(4), 545-550. (Read full article)
    46. Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer, 15(4), e599-e602. (Read full article)
    47. Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 8(20), 33614-33620. (Read full article)
    48. Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071. (Read full article)
    49. Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676. (Read full article)
    50. Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S (2016). Reversible Lysine-Specific Demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-myc in castration-resistant and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis.
    51. Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma S (2016). Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs, 34(2), 243-52. (Read full article)
    52. Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308. (Read full article)

    Review

    1. Mahlow J, Gupta S (2024). Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance. [Review]. Urol Oncol. (Read full article)
    2. Tripathi N, Fortuna GG, Gebrael G, Dal E, Mathew Thomas V, Gupta S, Swami U (2023). Predictors of response to neoadjuvant therapy in urothelial cancer. [Review]. Crit Rev Oncol Hematol, 194, 104236. (Read full article)
    3. Johnson ED, Butler K, Gupta S (2021). Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm. [Review]. Fed Pract, 38(Suppl 3), S20-S26. (Read full article)

    Editorial

    1. Butterfield A, Gupta S (2017). Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor. Transl Androl Urol, 6(6), 1198-1202. (Read full article)

    Abstract

    1. Manish Kohli Jodie Wong Yijun Tian Amir Bitaraf Claire Hanson Matt Larsen Jennifer Lloyd Julia Batten Neeraj Agarwal Umang Swami Benjamin Maughan Sumati Gupta Jonathan Tward (2023). Abstract 6023: Plasma methylome landscape across the spectrum of prostate cancer progression, and differentially methylated region (DMR) based biomarkers of hormonal therapy failure in metastatic hormone-sensitive prostate cancer [Abstract]. 83(7_Supplement), 6023.
    2. Umang Swami, Caitlin Faust, Samuel Leonhart, Benjamin Haaland, Kristen Jones, Haoran Li, Kamal Kant Kant Sahu, Vinay Mathew Thomas, Tenzin Kunsang Phunrab, Julia Batten, Lindsay Maxwell, Jennifer Lloyd, Manish Kohli, Sumati Gupta, Kelli Thorne, Benjamin L Maughan, Neeraj Agarwal Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT (2023). ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).   [Abstract]. 41(6_suppl), TPS294.
    3. Kamal Kant Kant Sahu, Nishita Tripathi, Beverly Chigarira, Nicolas Sayegh, Vinay Mathew Thomas, Haoran Li, Yeonjung Jo, Georges Gebrael, Puja Iyer, Roberto Nussenzveig, Neeraj Agarwal, Benjamin L Maughan, Sumati Gupta, Umang Swami Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT University of Utah, Salt Lake City, UT (2023). Characterization of the tumor transcriptomic differences by smoking history in locally advanced or metastatic urothelial carcinoma (UC).   [Abstract]. 41(6_suppl), 561.
    4. Jonathan David Tward, Skyler B Johnson, Kristine E Kokeny, Shane Lloyd, Donald Maurice Cannon, Christopher B Dechet, Brock ONeil, Robert Stephenson, Kenneth M Boucher, Sumati Gupta, Umang Swami, Benjamin L Maughan, Neeraj Agarwal Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT University of Utah, Salt Lake City, UT Huntsman Cancer Hospital, Salt Lake City, UT (2023). Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone. [Abstract]. 41(6_suppl), 156.
    5. Kamal Kant Kant Sahu, Haoran Li, Vinay Mathew Thomas, Mallory Benson, Josiah Hawaks, Julian Brown, Kelli Thorne, Kathy Sherwin, Jackson Cheney, Kenneth M Boucher, Sumati Gupta, Manish Kohli, Umang Swami, Neeraj Agarwal, Benjamin L Maughan Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT University of Utah, Salt Lake City, UT Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT Salt Lake City, UT (2023). A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR). [Abstract]. 41(6_suppl), 364.
    6. Petros Grivas, Damien Pouessel, Chandler H Park, Philippe Barthelemy, Manojkumar Bupathi, Daniel P Petrylak, Neeraj Agarwal, Sumati Gupta, Aude Flechon, Chethan Ramamurthy, Nancy B Davis, Alejandro Recio-Boiles, Cora N Sternberg, Astha Bhatia, Cabilia Pichardo, Mitch Sierecki, Julia Tonelli, Huafeng Zhou, Scott T Tagawa, Yohann Loriot (2023). Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.   [Abstract]. 41(6_suppl), 518.
    7. Sumati Gupta, Benjamin Maughan, Manish Kohli, Bradley Cairns, Umang Swami, Neeraj Agarwal (2022). A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)   [Abstract].
    8. S Gupta, A Hong, NN El-Chaar, C Young, K Ramaswamy, B Xie, S Bunner, B Diessner, U Swami (2022). Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) [Abstract].
    9. Nishita Tripathi Yeonjung Jo Nicolas Sayegh Beverly Chigarira Blake Nordblad Vinay Mathew Thomas Benjamin Haaland Roberto Nussenzveig Sumati Gupta Neeraj Agarwal Umang Swami Benjamin L Maughan (2022). Abstract 5955: Tumor genomic landscape in patients (pts) with and without liver metastasis in metastatic urothelial carcinoma (mUC).   [Abstract]. 82(12_Supplement), 5995.
    10. Sheetal Hardikar Christopher R Weil Shane Lloyd Jessica N Cohan Mark A Supiano Jennifer Ose Anita R Peoples Sumati V Gupta Kaitlyn Pelletier Martine Extermann Erin M Siegel David Shibata Cornelia M Ulrich (2022). Abstract 36: Treatment patterns in stage I-III colorectal cancer patients over 65 years of age [Abstract]. 82(12_Supplement), 36.
    11. Samantha Greenberg, Elizabeth Orlando, Morgan Devlin, Sara Low, Amanda Anson, Brock O Neil, Wendy Kohlmann, Bob Wong, Christopher B Dechet, Alejandro Sanchez, Jonathan David Tward, Skyler B Johnson, Neeraj Agarwal, Manish Kohli, Sumati Gupta, Umang Swami, Benjamin L Maughan Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Huntsman Cancer Institute, Salt Lake City, UT University of Utah, Salt Lake City, UT (2022). Comparing pretest video genetic education for prostate cancer patients: Do patients need assistance?  [Abstract]. 40(16_suppl), 5061.
    12. Wendy Kohlmann, David Nix, Aaron Atkinson, Kenneth M Boucher, Jill Kolesar, Eric A Singer, Stephen B Edge, Branda Quintana, Michelle L Churchman, Bingjian Feng, Laura Graham, John D Carpten, Alejandro Sanchez, Yousef Zakharia, Lindsey Byrne, Rohit K Jain, Kenneth G Nepple, Ahmad Shabsigh, Jad Chahoud, and Sumati Gupta (2022). Inherited germline variants in urothelial cancer: A multicenter whole-exome sequencing analysis [Abstract].
    13. Shilpa Gupta, Ewan Gibb, Guru P Sonpavde, Sumati Gupta, Benjamin L Maughan, Neeraj Agarwal, Bradley Alexander McGregor, Christopher Weight, Xiao X Wei, David Johnson Einstein, Christopher B Dechet, Mark A Preston, Matthew Mossanen, Bharat Thygarajan, Markus Eckstein, C Marcela Diaz-Montero, Paari J Murugan, Peter C Black, Badrinath R Konety (2022). Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.   [Abstract]. 40(6_suppl), 528.
    14. Neal Shiv Chawla, Nishita Tripathi, Nicolas Sayegh, Ameish Govindarajan, Nazli Dizman, Zeynep Busra Zengin, Luis A Meza, Ramya Muddasani, Alex Chehrazi-Raffle, Sabrina Salgia, Jasnoor Malhotra, Joann Hsu, Errol James Philip, Cristiane Decat Bergerot, Yung Lyou, Umang Swami, Sumati Gupta, Benjamin L Maughan, Neeraj Agarwal, Sumanta K Pal (2022). Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. [Abstract]. 40(6_suppl), 561.
    15. Shilpa Gupta, Guru Sonpavde, Christopher J Weight, Bradley Alexander McGregor, Sumati Gupta, Benjamin Louis Maughan, Xiao X Wei, Ewan Gibb, Bharat Thyagarajan, David Johnson Einstein, Christopher B Dechet, William Thomas Lowrance, Paari J Murugan, Kerry L Kilbridge, Neeraj Agarwal, Elai Davicioni, Markus Eckstein, Matthew Mossanen, Mark A Preston, and Badrinath R Konety (2020). Pl Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. [Abstract]. 38(6_suppl), 439-439.
    16. Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean H Hoffman-Censits, David I Quinn, Daniel Peter Petrylak, Matt D Galsky, Ulka N Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A Burris III, Jessica Rearden, Corina Andresen, Hao Wang, Siamak Daneshmand, Dean F Bajorin, and Sumanta K Pal (6/2020). Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.   [Abstract]. 38(15_suppl), 5038-5038.
    17. Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, and Guru Sonpavde (6/2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.   [Abstract]. 38(15_suppl), 5043-5043.
    18. Lesli Ann Kiedrowski, Roby Antony Thomas, Nicholas J Vogelzang, Guru Sonpavde, Sumati Gupta, Theodore Stewart Gourdin, Bishoy Morris Faltas, Rebecca Nagy, Richard B Lanman, and Petros Grivas (6/2020). FGFR2/3 genomic alterations (GA) in cell-free (cf)DNA from patients (pts) with advanced urothelial carcinoma (aUC).   [Abstract]. 38(6_suppl), 565-565.
    19. Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean H Hoffman-Censits, David I Quinn, Daniel Peter Petrylak, Matt D Galsky, Ulka N Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A Burris, Jessica Rearden, Yining Ye, Hao Wang, Susan Moran, Siamak Daneshmand, Dean F Bajorin, and Sumanta K Pal (06/2020). Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC).     [Abstract]. 38(6_suppl), 576-576.
    20. Petros Grivas, Yohann Loriot, Susan Feyerabend, Rafael Morales-Barrera, Min Yuen Teo, Nicholas J Vogelzang, Enrique Grande, Yousef Zakharia, Nabil Adra, Ajjai Shivaram Alva, Andrea Necchi, Sumati Gupta, Debra Hannah Josephs, Alejo Rodriguez-Vida, Sandy Srinivas, Kenton Wride, Daleen Thomas, Rachel Dusek, Dale L Nepert, and Simon Chowdhury (06/2020). Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial.   [Abstract]. 38(6_suppl), 440-440.
    21. Benjamin Louis Maughan, Andrew W Hahn, Roberto Nussenzveig, John Hoffman, Kathryn Morton, Sumati Gupta, Julia Anne Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M Boucher, Benjamin Haaland, and Neeraj Agarwal (6/2020). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. [Abstract]. 38(6_suppl), 125-125.
    22. Benjamin Louis Maughan, Alejandro Sanchez, Brock B ONeil, William Thomas LowranceChristopher B Dechet, Danel Joseph Albertson, Deepika Sirohi, Sumati Gupta, Umang Swami, and Neeraj Agarwal (6/2020). A phase 1b/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AteoVax). [Abstract]. 38(6_suppl), TPS382-TPS382.
    23. Benjamin Louis Maughan, Roberto Nussenzveig, Umang Swami, Sumati Gupta, and Neeraj Agarwal (06/2020). Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response. [Abstract]. 38(6_suppl), TPS267-TPS267.
    24. Sergiusz Wesolowski Roberto Nussenzveig, Victor Sacristan Santos, John Esther, Divyam Goel, Umang Swami, Sumati Gupta, Benjamin Louis Maughan, Mark Yandell, Petros Grivas, and Neeraj Agarwal (6/2020). Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI). [Abstract]. 38(6_suppl), 570-570.
    25. Sumati Gupta, Benjamin Louis Maughan, Christopher B Dechet, William Thomas Lowrance, Brock O Neil, Kristine E Kokeny, Shane Lloyd, Jonathan David Tward, Kenneth M Boucher, and Neeraj Agarwal (2020). NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. [Abstract]. 38(6_suppl), TPS605-TPS605.
    26. A NecchiD Pouessel, R Leibowitz-Amit, A Flechon, S Gupta, P Barthelemy, M Maio, X Zhu, E Asatiani, G Serbest, H Zhen, Y Loriot (10/01/2018). Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). [Abstract]. ESMO Annual Meeting 2018.
    27. Gupta, S (10/01/2018).  ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma. [Abstract]. ESMO Annual Meeting 2018.
    28. Petros Grivas, Gregory Russell Pond, Rebecca J Nagy, Pedro C Barata, Prateek Mendiratta, Dharmesh Gopalakrishnan, Alexandra Drakaki, Sumati Gupta, Neeraj Agarwal, Jue Wang, Bishoy Faltas, Ulka N Vaishampayan, Gurudatta Naik, Bradley Alexander McGregor, Sumanta K Pal, Lesli Ann Kiedrowski, Richard B Lanman, Guru Sonpavde (06/01/2018). Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). ASCO Annual Meeting 2018 [Abstract].
    29. Jacob Adashek, Sumanta K Pal, Vincent M Chung, Scott T Tagawa, Joel Picus, Hani M Babiker, Sumati Gupta, Raymond Couric Wadlow, Julie Poore, Christine Peterson, Ely Benaim (2018). Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC). ASCO Annual Meeting 2018 [Abstract].
    30. Sumati Gupta, Andrew Butterfield, Timothy Parnell, Alexis Weston, Mohan Kaadige, Sunil Sharma (2018). Reversible LSD1 (KDM1A) inhibition with HCI2509 is growth inhibitory in bladder cancer cell lines and causes gene expression changes that reveal rational therapeutic partners [Abstract]. Presented at Targeting DNA Methylation and Chromatin for Cancer Therapy in Atlanta March 2018.
    31. Ahmad Halwani, Zachary Burningham, Kelli M Rasmussen, Vikas Patil, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer (2017). Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Evidence From the Veterans Health Administration [Abstract]. ESMO Annual Meeting 2017.
    32. Sumanta Pal, Vincent Chun, Scott Tagawa, Joel Picus, Sumati Gupta, Julie Poore, Christine Peterson and Ely Benaim (2017). RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Metastatic Bladder Cancer [Abstract]. ESMO Annual Meeting 2017.
    33. Pandha HS, Ralph C, Harrington K, Curti BD, Sanborn RE, Akerley WL, Gupta S, Rudin CM, Rosenberg JE, Kaufman DR, Schmidt EV, Grose M, Shafren D (2017). Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients [Abstract]. ASCO Annual Meeting 2017.
    34. Gong J, Chung VM, Picus J, Tagawa ST, Gupta S, Poore J, Peterson C, Benaim E, Pal SK (2017). Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study. [Abstract]. ASCO Annual Meeting 2017.
    35. Choueiri TK, Larkin JMG, Oya M, Thistlethwaite FC, Martignoni M, Nathan PD, Powles T, McDermott DF, Robbins PB, Chism DD, Cho DC, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, di Pietro A, Rini BI (2017). First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. [Abstract]. ASCO Annual Meeting 2017.
    36. Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde G (2017). Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape [Abstract]. ASCO Annual Meeting 2017.
    37. Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer, Ahmad Halwani (2017). The role of academic affiliation in the treatment of metastatic castrate-resistant prostate cancer in the Veterans Health Administration Abstract- AVAHO 2017 [Abstract]. AVAHO 2017.
    38. Ahmad Halwani, Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie N Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C, Saier (2017). Racial Disparities in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Evidence from the Veteran’s Health Administration (VHA) AACR [Abstract]. Prostate Cancer: Advances in Basic, Translational, and Clinical Research meeting 2017.
    39. Gupta S, Albertson DJ, Parnell T, Dalley B, O Shea J, Weston A, Butterfield A, Pappas LM, Schiffman JD, Sharma S, Agarwal N (2017). Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC) [Abstract]. GU ASCO 2017.
    40. Gupta S, Albertson DJ, Gaston D, Heilbrun ME, Agarwal N, Liu T, Miller VA, Ross JS, Milis SZ, Ali SM (2017). Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients [Abstract]. GU ASCO 2017.
    41. Hahn AW, Gill DM, Streeter J, Bailey EB, Carroll E, Aryal L, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC) [Abstract]. GU ASCO 2017.
    42. Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde G (2017). Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy. [Abstract]. GU ASCO 2017.
    43. Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher KM, Maughan BL, Agarwal N (2017). Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). [Abstract]. GU ASCO 2017.
    44. Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer [Abstract]. GU ASCO 2017.
    45. Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn, AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC) [Abstract]. GU ASCO 2017.
    46. Stenehjem D, Gupta S, Wade M, Gilcrease G, Garrido-Laguna I, Weis JR, Whisenant J, Sharma S (2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies [Abstract]. Center for Investigational Therapeutics, Huntsman Cancer Institute, Salt Lake City, UT, USA, 2016.
    47. Agarwal N, Heemers H, Farnham JM, Patel SB, Gill D, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. 2016 ASCO.
    48. Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz AA, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urotheial carcinoma of the bladderÏ [Abstract]. ASCO Annual Meeting 2016.
    49. Gupta S (2016). A Phase 2 Study of the Histone Deacetylase (HDAC) Inhibitor Mocetinostat in Patients with Urothelial Carcinoma (UC) and Inactivating Alterations of Acetyltransferase Genes [Abstract]. ASCO 2015 Annual Meeting.
    50. Gupta S, Weston A, Bearrs J, Soldi R, Sharma S (2015). Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells [Abstract]. AACR Annual Meeting, April 2015.
    51. Gupta S (2002). Retrospective study on the effect of chronic ACE inhibitor therapy on inter-dialysis weight gain in patients on hemodialysis [Abstract]. Ren Fail, Jul;24(4), 461-6.

    Other

    1. Hillary Finch, Clark Low, Sumati Gupta (2018). FGFR pathways and their role in oncologic therapy: Focus on Phase I Newsletter. Focus on Phase I Newsletter.
    2. Nikita Pandya, Robert Hanlon, Andrew Butterfield, Sumati Gupta (2017). Epigenetics in Cancer: A Review. Can Stu The J 2017.
    3. Kharkar VJ, Ast A, Gupta S, Sharma S (2016). LSD2/KDM1B/AOF1 and Human Cancer Pathways: A Literature Review. Can Stu The J (1(1), pp. 1-5).
    4. Gupta S (2015). Epigenetics in Bladder Cancer. Focus on Phase I Newsletter.